Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Zealand Pharma Clear all
Completed Phase 3 Interventional Results available

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT03777176
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Dasiglucagon, Standard of Care
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
3 Months to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

NCT03690206
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
glepaglutide, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Bihormonal iLet Bionic Pancreas Feasibility Study

NCT03840278
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Bihormonal iLet Bionic Pancreas, Insulin-only Bionic Pancreas, Dasiglucagon
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 2 Interventional

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

NCT06662539
View directory record Official record
Conditions
Obesity
Interventions
Petrelintide, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Boca Raton, Florida • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Trial Testing the Bionic Pancreas With ZP4207

NCT02971228
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
Drug · Device
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

NCT03378635
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Dasiglucagon, GlucaGen, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 6, 2026, 1:02 PM EDT
Active, not recruiting Phase 3 Interventional

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

NCT02446405
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, NSAA, LHRHA or Surgical Castration
Drug
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 6, 2026, 1:02 PM EDT
Recruiting Phase 3 Interventional

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Glepaglutide, Placebo
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

NCT03667053
View directory record Official record
Conditions
Hypoglycemia
Interventions
dasiglucagon, placebo, GlucaGen HypoKit
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Escondido, California • New Haven, Connecticut • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

NCT03905707
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
glepaglutide
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

NCT05378672
View directory record Official record
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
Up to 5 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

NCT03216226
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
dasiglucagon, GlucaGen
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Orlando, Florida • Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 1 Interventional

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

NCT00868660
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
ZP1848
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 6, 2026, 1:02 PM EDT
Terminated Phase 2 Interventional

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

NCT00283361
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
ZP120, I.v. catherization, 6-minutes walk performance, Dyspnea severity assessment, Blood sampling for laboratory tests, ECG, Physical examination
Drug · Procedure · Behavioral
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
22
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

NCT03279302
View directory record Official record
Conditions
Healthy Subjects
Interventions
Glepaglutide
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

NCT03688711
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chula Vista, California • Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT04172441
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
7 Days to 364 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT03941236
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
5 Weeks to 13 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

NCT06926842
View directory record Official record
Conditions
Overweight, Type 2 Diabetes, Obesity
Interventions
Petrelintide, Placebo
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
48
States / cities
Cullman, Alabama • Chandler, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 6, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

NCT04881825
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Glepaglutide
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 6, 2026, 1:02 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

NCT07228403
View directory record Official record
Conditions
Short Bowel Syndrome (SBS)
Interventions
Glepaglutide 10 mg
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Rochester, Minnesota • Omaha, Nebraska • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 6, 2026, 1:02 PM EDT